EFFICACY OF MIDODRINE AND OCTREOTIDE (MIDO/OCTR) ON THE OUTCOME OF TYPE 1 HEPATORENAL SYNDROME (HRS-1) AT A UNIVERSITY TRANSPLANT CENTER

被引：0
|
作者：
Karim, Yasmin K. [1 ]
Liu, Eashen M. [1 ]
Lewis, James H. [1 ]
机构：
[1] Georgia Univ Hosp, Dept Gastroenterol, Washington, DC USA
来源：
HEPATOLOGY | 2008年 / 48卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1704
引用
收藏
页码：1068A / 1068A
页数：1
相关论文
共 50 条
  • [1] Outcomes in 46 PTS with type 1 Hepatorenal synd (Hrs-1) treated with Midodrine and octreotide (Mido/Octr): Correlation with underlying liver disease and patient demographics
    Karim, Yasmin
    Liu, Eashen
    Lewis, James
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S142 - S143
  • [2] Efficacy of Midodrine, Octreotide and Albumin (MOA) for Type I Hepatorenal Syndrome (HRS 1)
    Liu, Eashen
    Singhal, Pooja
    Karim, Yasmin K.
    Barton, Franca B.
    Lewis, James H.
    GASTROENTEROLOGY, 2011, 140 (05) : S959 - S959
  • [3] Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide
    Angeli, P
    Volpin, R
    Gerunda, G
    Craighero, R
    Con, P
    Caregaro, L
    Cameriero, V
    Sticca, A
    MaffeiFaccioli, A
    Gatta, A
    HEPATOLOGY, 1997, 26 (04) : 635 - 635
  • [4] Vasoactive treatment of hepatorenal syndrome type 1 (HRS1) with midodrine, octreotide and albumin
    Schepke, M
    Malayeri, H
    Heller, J
    Sauerbruch, T
    GASTROENTEROLOGY, 2003, 124 (04) : A664 - A664
  • [5] Is Midodrine, Octreotide, and Albumin still worthwhile therapy for Hepatorenal Syndrome Type 1 (HRS1)?
    Hahn, Katherine
    Javaid, Amen
    Singhal, Pooja
    Barton, Franca B.
    Lewis, James H.
    HEPATOLOGY, 2015, 62 : 358A - 358A
  • [6] Terlipressin is superior to midodrine/octreotide for hepatorenal syndrome type 1
    Kalambokis, Georgios N.
    Baltayiannis, Gerasimos
    Christodoulou, Dimitrios
    Christou, Leonidas
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (12) : 1428 - 1429
  • [7] Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide
    Angeli, P
    Volpin, R
    Gerunda, G
    Craighero, R
    Rone, P
    Merenda, R
    Amodio, P
    Sticca, A
    Caregaro, L
    Maffei-Faccioli, A
    Gatta, A
    HEPATOLOGY, 1999, 29 (06) : 1690 - 1697
  • [8] Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome
    Wong, F
    Pantea, L
    Sniderman, K
    HEPATOLOGY, 2004, 40 (01) : 55 - 64
  • [9] Impact of Terlipressin on Serum Sodium Levels in Patients with Hepatorenal Syndrome Type 1 (HRS-1): CONFIRM Study
    Pyrsopoulos, Nikolaos
    Khan, Mohammad
    Zafar, Zunaira
    Jamil, Khurram
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S877 - S878
  • [10] SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) IS A MAJOR DETERMINANT OF TREATMENT RESPONSE TO TERLIPRESSIN FOR HEPATORENAL SYNDROME TYPE 1 (HRS-1)
    Wong, F.
    Pappas, S. C.
    Boyer, T. D.
    Sanyal, A. J.
    Jamil, K.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S235 - S236
12345